Polyneuropathy, the most common form of peripheral neuropathy, is a condition in which neurons of the peripheral nervous system dysfunction progressively, over time, in a length dependent manner–the longest neurons being initially affected followed by sequentially shorter neurons.  Many factors contribute to polyneuropathy but as with degenerative diseases of the nervous system such as Alzheimer’s disease and Parkinson’s disease, mitochondrial dysfunction–causing decreased ATP production and intraneuronal energy deficiency–may represent a common mechanism.

The ability of peripheral neurons to conduct action potentials is dependent upon, among other factors, the maintenance of a precise gradient of sodium and potassium ions across the neuronal cell membrane.  The sodium-potassium pump, an array of membrane-resident macromolecules, maintains this gradient and, in so doing, consumes the majority of ATP produced by neuronal mitochondria.  Inefficiencies in the functioning of the pump have been shown to cause polyneuropathy–as demonstrated in studies showing decreased pump activity, structural variations which decrease pump efficiency and fewer pumps molecules.

Because the pump consumes the majority of energy produced by neuronal mitochondria, it would be reasonable to hypothesize that damage to mitochondria or other conditions that impair ATP production would cause decreased pump activity and result in polyneuropathy.

The work of Bennett, et al. appears to support this hypothesis.  They argue that cancer chemotherapy, HIV infection, and diabetes damage the mitochondria of peripheral sensory neurons–a condition they call mitotoxicity–reducing energy availability and causing distal symmetrical sensory peripheral neuropathy.

This hypothesis is also consistent with polyneuropathies associated with thiamine deficiency– diabetic polyneuropathy, alcoholic polyneuropathy, and others–in which thiamine deficiency impairs carbohydrate metabolism and reduces intraneuronal ATP production.  These polyneuropathies often improve with thiamine replacement therapy and the increased ATP levels associated with it.

Although the causes of polyneuropathy are certainly multifactorial, decreased intraneuronal energy availability and its effect on sodium-potassium pump efficiency appear to be a factor in multiple etiologies.  This hypothesis is supported by observations that mitochondrial damage and thiamine deficiency–both of which decrease intraneuronal energy availability–are often associated with polyneuropathy.

A request from the author:
Have any of your patients who have taken NeuRemedy experienced any benefits in addition to improvement in their neuropathic symptoms? If so, I would like to know. Please contact me at rhm123@gmail.com or call me at 561-549-9099.

Dr. Mann bust-shotDr. Richard H Mann, DABPS, ret
Chief Scientific Officer & Founder, Realm Labs

If you would like to speak with Dr. Mann about how to improve your outcomes in the treatment of polyneuropathy call 866-634-2745 or email Dr. Mann at realmlabs123@gmail.com

Dr. Mann is the developer of the  NeuRemedy®line of benfotiamine nutritional supplements. NeuRemedy is a safe, proven, and effective nutritional formulation dispensed by physicians to their patients suffering from numbness, tingling, burning and/or shooting pains in the feet and legs.  Thiamine (vitamin B1) deficiency often accompanies and intensifies these symptoms. The reversal of thiamine deficiency is an important therapeutic goal in the management of these patients.*

The key ingredient in NeuRemedy, benfotiamine, is the most highly bioactive oral form of thiamine available. It rapidly and safely reverses thiamine deficiency, improving the functioning of the nerves in the feet and legs. Each capsule of NeuRemedy contains 150 mg of benfotiamine in a proprietary formulation. Because of its impressive success rate and high safety profile, NeuRemedy was recently licensed in Canada as an important factor in supporting healthy nerve function in individuals with polyneuropathy.*

NeuRemedy is the leader in the field with thousands of physicians and patients relying each day on its efficacy, purity, safety and rapid onset of action.*

For more information on NeuRemedy:
In the USA contact Realm Labs at 866-634-2745.
In Canada contact OHI at 855-561-4156.

Leave a Reply

Your email address will not be published. Required fields are marked *